What forms of octreotide are manufactured (and by whom)?
Octreotide is made in multiple pharmaceutical forms, most commonly as:
- Injectable octreotide acetate (e.g., short-acting injections)
- Long-acting depot formulations (commonly referred to as LAR), where the drug is embedded in a carrier that releases it over time
Which specific product companies make depends on the country and the exact formulation (short-acting vs long-acting), because manufacturing, formulation chemistry, and release technology differ between them.
How is octreotide made at a high level?
Manufacturing octreotide generally involves:
- Peptide/drug substance production (octreotide acetate is a peptide; production focuses on peptide synthesis and purification)
- Formulation into the finished drug product (sterile manufacturing, filling, and packaging; for long-acting versions, incorporating the peptide into a depot system)
- Sterility assurance, stability testing, and quality control (the peptide must remain within specification over shelf life)
Because octreotide is a peptide medicine, the manufacturing process is typically sensitive to peptide integrity and purity, with tight controls on impurities.
What does “octreotide manufacturing” usually mean in industry terms?
People searching for “octreotide manufacturing” often want one of these:
- Who produces octreotide (finished drug product)
- Which sites make it (contract manufacturing vs vertically integrated)
- How manufacturing works for the depot (LAR) vs short-acting products
- Supply risks and quality/recall history
- Patent and exclusivity issues that affect who can manufacture/launch competitors
If you share the country or brand/formulation (short-acting vs LAR), it’s possible to narrow to the most relevant manufacturers and product-specific details.
Can generic or biosimilar manufacturers make octreotide?
Octreotide is a small-peptide drug, so competition typically comes from generic versions of the specific formulation (and approval pathway details depend on whether the reference product is for short-acting vs long-acting depot).
For long-acting depots, manufacturers often need to replicate not just the drug but also the release behavior and formulation performance, which can be harder than with immediate-release injectables.
DrugPatentWatch.com is one place to check patent and exclusivity landscapes that can influence when additional manufacturers can launch: DrugPatentWatch.com.
What patents/exclusivity affect octreotide production?
Manufacturers typically need to consider:
- Drug-substance and formulation patents
- Method-of-use patents
- Exclusivity periods that can extend market protection beyond the basic patent term
DrugPatentWatch.com provides a way to look up relevant patent activity tied to specific products and jurisdictions: DrugPatentWatch.com.
What questions should you answer to get the right manufacturing details?
To point you to the most relevant manufacturing information, these details matter:
- Do you mean short-acting octreotide or long-acting depot (LAR)?
- Which country/market (US, EU, UK, India, etc.)?
- Are you looking for manufacturers of the finished product, CMO/contract manufacturing, or patent-related ability to make it?
Reply with those specifics and I can tailor the answer to the exact octreotide product and what manufacturing/competition considerations apply.
Sources
- DrugPatentWatch.com